138 related articles for article (PubMed ID: 9472094)
1. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma.
Stack MS; Ellerbroek SM; Fishman DA
Int J Oncol; 1998 Mar; 12(3):569-76. PubMed ID: 9472094
[TBL] [Abstract][Full Text] [Related]
2. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma.
Moser TL; Young TN; Rodriguez GC; Pizzo SV; Bast RC; Stack MS
Int J Cancer; 1994 Feb; 56(4):552-9. PubMed ID: 8112891
[TBL] [Abstract][Full Text] [Related]
3. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells.
Fishman DA; Bafetti LM; Banionis S; Kearns AS; Chilukuri K; Stack MS
Cancer; 1997 Oct; 80(8):1457-63. PubMed ID: 9338470
[TBL] [Abstract][Full Text] [Related]
4. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells.
Fishman DA; Bafetti LM; Stack MS
Invasion Metastasis; 1996; 16(3):150-9. PubMed ID: 9186550
[TBL] [Abstract][Full Text] [Related]
5. Biochemical characterization of primary peritoneal carcinoma cell adhesion, migration, and proteinase activity.
Fishman DA; Chilukuri K; Stack MS
Gynecol Oncol; 1997 Nov; 67(2):193-9. PubMed ID: 9367707
[TBL] [Abstract][Full Text] [Related]
6. Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro.
Dolo V; D'Ascenzo S; Violini S; Pompucci L; Festuccia C; Ginestra A; Vittorelli ML; Canevari S; Pavan A
Clin Exp Metastasis; 1999 Mar; 17(2):131-40. PubMed ID: 10411105
[TBL] [Abstract][Full Text] [Related]
7. [Regulation of matrix-degrading enzymes in gynecologic cancer tissues and cells].
Kikkawa F
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):618-22. PubMed ID: 8808829
[TBL] [Abstract][Full Text] [Related]
8. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles.
Graves LE; Ariztia EV; Navari JR; Matzel HJ; Stack MS; Fishman DA
Cancer Res; 2004 Oct; 64(19):7045-9. PubMed ID: 15466198
[TBL] [Abstract][Full Text] [Related]
9. Analysis of matrix metalloproteinases and related tissue inhibitors in cystic fluids of ovarian tumors.
Furuya M
Hokkaido Igaku Zasshi; 1999 Mar; 74(2):145-55. PubMed ID: 10386163
[TBL] [Abstract][Full Text] [Related]
10. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin.
Moser TL; Pizzo SV; Bafetti LM; Fishman DA; Stack MS
Int J Cancer; 1996 Sep; 67(5):695-701. PubMed ID: 8782661
[TBL] [Abstract][Full Text] [Related]
11. Establishment of long-term in vitro cultures of human ovarian cystadenomas and LMP tumors and examination of their spectrum of expression of matrix-degrading proteinases.
Luo MP; Gomperts B; Imren S; DeClerck YA; Ito M; Velicescu M; Felix JC; Dubeau L
Gynecol Oncol; 1997 Dec; 67(3):277-84. PubMed ID: 9441775
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade.
Ahmed N; Pansino F; Clyde R; Murthi P; Quinn MA; Rice GE; Agrez MV; Mok S; Baker MS
Carcinogenesis; 2002 Feb; 23(2):237-44. PubMed ID: 11872628
[TBL] [Abstract][Full Text] [Related]
13. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion.
Ellerbroek SM; Hudson LG; Stack MS
Int J Cancer; 1998 Oct; 78(3):331-7. PubMed ID: 9766568
[TBL] [Abstract][Full Text] [Related]
14. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells.
Rosanò L; Varmi M; Salani D; Di Castro V; Spinella F; Natali PG; Bagnato A
Cancer Res; 2001 Nov; 61(22):8340-6. PubMed ID: 11719468
[TBL] [Abstract][Full Text] [Related]
15. Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinoma.
Gurler Main H; Xie J; Muralidhar GG; Elfituri O; Xu H; Kajdacsy-Balla AA; Barbolina MV
Oncogene; 2017 May; 36(21):3025-3036. PubMed ID: 27941884
[TBL] [Abstract][Full Text] [Related]
16. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion.
Jeong KJ; Park SY; Cho KH; Sohn JS; Lee J; Kim YK; Kang J; Park CG; Han JW; Lee HY
Oncogene; 2012 Sep; 31(39):4279-89. PubMed ID: 22249252
[TBL] [Abstract][Full Text] [Related]
17. Cadherin composition and multicellular aggregate invasion in organotypic models of epithelial ovarian cancer intraperitoneal metastasis.
Klymenko Y; Kim O; Loughran E; Yang J; Lombard R; Alber M; Stack MS
Oncogene; 2017 Oct; 36(42):5840-5851. PubMed ID: 28628116
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide (As(2)O(3)) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo.
Zhang J; Wang B
Gynecol Oncol; 2006 Oct; 103(1):199-206. PubMed ID: 16624393
[TBL] [Abstract][Full Text] [Related]
19. Role for different cell proteinases in cancer invasion and cytolysis.
Zucker S; Beck G; DiStefano JF; Lysik RM
Br J Cancer; 1985 Aug; 52(2):223-32. PubMed ID: 2992566
[TBL] [Abstract][Full Text] [Related]
20. Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells.
Miyagi E; Yasumitsu H; Hirahara F; Minaguchi H; Koshikawa N; Miyazaki K; Umeda M
Jpn J Cancer Res; 1995 Jun; 86(6):568-76. PubMed ID: 7622422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
